Screening for modulators of glioma stem cells differentiation View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2013-2016

FUNDING AMOUNT

1044772 USD

ABSTRACT

DESCRIPTION (provided by applicant): Gliomas account for about 60% of all primary CNS tumors. Glioblastoma (GBM) or grade IV gliomas which comprise 50.9% of all gliomas are the most malignant form. Glioblastoma tumors are highly heterogeneous and there is a complex interaction among different types of tumor cells and stromal cells within the tumor. Recently it has been shown that the majority of tumor cells do not have the capacity to recapitulate a phenocopy of the original tumor and that only a small subpopulation of cells in the tumor, called cancer stem cells, have that ability upon xenotransplantation in nude mice. According to the cancer stem cell hypothesis, molecular alterations in cancer either convert normal stem cells into aberrant counterparts or cause a more differentiated cell to revert towards a stem cell-like behavior. These cancer stem cells appear to be more resistant to conventional therapy, as compared to the non-cancer stem cells. Following current therapy for high-grade glioma tumors, most patients die within a year from a new secondary tumor foci forming within one centimeter of the resected area. These foci are enriched for cancer stem cells, and it is likely that they are responsible for tumor recurrence. Targeted therapies aiming at eradication of glioma stem cells, or reverting these cells into a more differentiated state which can then responds to conventional therapy is highly beneficial and are current being tested in clinical trials using all-trans retinoc acids (ATRA; ://clinicaltrials.gov). In this proposal, we will optimize a triple secreted reporter system for high-throughput screening and use it to find modulators of glioma stem cells. We will simultaneously screen for drugs which either: (1) revert glioblastoma cancer stem cells into a more differentiated state, making them susceptible to conventional therapy; (2) eradicate these cells. Potential drug hits will then be analyzed in an intracranial glioma stem cells model which infiltrates the brain of mice similar to human tumors. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=8785102

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "1044772"
    }, 
    "description": "DESCRIPTION (provided by applicant): Gliomas account for about 60% of all primary CNS tumors. Glioblastoma (GBM) or grade IV gliomas which comprise 50.9% of all gliomas are the most malignant form. Glioblastoma tumors are highly heterogeneous and there is a complex interaction among different types of tumor cells and stromal cells within the tumor. Recently it has been shown that the majority of tumor cells do not have the capacity to recapitulate a phenocopy of the original tumor and that only a small subpopulation of cells in the tumor, called cancer stem cells, have that ability upon xenotransplantation in nude mice. According to the cancer stem cell hypothesis, molecular alterations in cancer either convert normal stem cells into aberrant counterparts or cause a more differentiated cell to revert towards a stem cell-like behavior. These cancer stem cells appear to be more resistant to conventional therapy, as compared to the non-cancer stem cells. Following current therapy for high-grade glioma tumors, most patients die within a year from a new secondary tumor foci forming within one centimeter of the resected area. These foci are enriched for cancer stem cells, and it is likely that they are responsible for tumor recurrence. Targeted therapies aiming at eradication of glioma stem cells, or reverting these cells into a more differentiated state which can then responds to conventional therapy is highly beneficial and are current being tested in clinical trials using all-trans retinoc acids (ATRA; ://clinicaltrials.gov). In this proposal, we will optimize a triple secreted reporter system for high-throughput screening and use it to find modulators of glioma stem cells. We will simultaneously screen for drugs which either: (1) revert glioblastoma cancer stem cells into a more differentiated state, making them susceptible to conventional therapy; (2) eradicate these cells. Potential drug hits will then be analyzed in an intracranial glioma stem cells model which infiltrates the brain of mice similar to human tumors.", 
    "endDate": "2016-03-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2481830", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2481830"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01CA166077"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "new secondary tumor foci", 
      "Targeted therapies", 
      "brain", 
      "malignant form", 
      "triple", 
      "conventional therapy", 
      "glioblastoma cancer stem cells", 
      "modulators", 
      "xenotransplantation", 
      "mice", 
      "capacity", 
      "drugs", 
      "focus", 
      "description", 
      "original tumor", 
      "years", 
      "differentiated state", 
      "applicants", 
      "stem cell-like behavior", 
      "molecular alterations", 
      "current therapies", 
      "glioma stem cell differentiation", 
      "cancer stem cells", 
      "majority", 
      "glioma stem cells", 
      "cancer", 
      "ability", 
      "Potential drug hits", 
      "primary CNS tumors", 
      "different types", 
      "cells", 
      "differentiated cells", 
      "glioma", 
      "grade IV gliomas", 
      "high-grade glioma tumors", 
      "eradication", 
      "centimeters", 
      "human tumors", 
      "stromal cells", 
      "Gliomas account", 
      "high-throughput screening", 
      "resected area", 
      "small subpopulation", 
      "reporter system", 
      "tumor cells", 
      "cancer stem cell hypothesis", 
      "normal stem cells", 
      "tumor recurrence", 
      "phenocopy", 
      "glioblastoma", 
      "clinical trials", 
      "most patients", 
      "complex interactions", 
      "glioblastoma tumors", 
      "ATRA", 
      "proposal", 
      "intracranial glioma stem cells model", 
      "trans retinoc acids", 
      "non-cancer stem cells", 
      "aberrant counterparts", 
      "nude mice", 
      "tumor"
    ], 
    "name": "Screening for modulators of glioma stem cells differentiation", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.32224.35", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.32224.35", 
          "name": "MASSACHUSETTS GENERAL HOSPITAL", 
          "type": "Organization"
        }, 
        "familyName": "TANNOUS", 
        "givenName": "BAKHOS A.", 
        "id": "sg:person.01274336034.51", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01274336034.51", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2481830"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_7.xml.gz", 
    "startDate": "2013-01-18T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8785102"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2481830'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2481830'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2481830'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2481830'


 

This table displays all metadata directly associated to this object as RDF triples.

106 TRIPLES      19 PREDICATES      84 URIs      76 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2481830 schema:about anzsrc-for:2211
2 schema:amount Ne054f778eb1a4571a4b2f19d3ee8d65b
3 schema:description DESCRIPTION (provided by applicant): Gliomas account for about 60% of all primary CNS tumors. Glioblastoma (GBM) or grade IV gliomas which comprise 50.9% of all gliomas are the most malignant form. Glioblastoma tumors are highly heterogeneous and there is a complex interaction among different types of tumor cells and stromal cells within the tumor. Recently it has been shown that the majority of tumor cells do not have the capacity to recapitulate a phenocopy of the original tumor and that only a small subpopulation of cells in the tumor, called cancer stem cells, have that ability upon xenotransplantation in nude mice. According to the cancer stem cell hypothesis, molecular alterations in cancer either convert normal stem cells into aberrant counterparts or cause a more differentiated cell to revert towards a stem cell-like behavior. These cancer stem cells appear to be more resistant to conventional therapy, as compared to the non-cancer stem cells. Following current therapy for high-grade glioma tumors, most patients die within a year from a new secondary tumor foci forming within one centimeter of the resected area. These foci are enriched for cancer stem cells, and it is likely that they are responsible for tumor recurrence. Targeted therapies aiming at eradication of glioma stem cells, or reverting these cells into a more differentiated state which can then responds to conventional therapy is highly beneficial and are current being tested in clinical trials using all-trans retinoc acids (ATRA; ://clinicaltrials.gov). In this proposal, we will optimize a triple secreted reporter system for high-throughput screening and use it to find modulators of glioma stem cells. We will simultaneously screen for drugs which either: (1) revert glioblastoma cancer stem cells into a more differentiated state, making them susceptible to conventional therapy; (2) eradicate these cells. Potential drug hits will then be analyzed in an intracranial glioma stem cells model which infiltrates the brain of mice similar to human tumors.
4 schema:endDate 2016-03-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier N498d26a40d154a86863b02f2f9f7b359
7 Na2252f334af94b0db2c3418d3e087682
8 schema:inLanguage en
9 schema:keywords ATRA
10 Gliomas account
11 Potential drug hits
12 Targeted therapies
13 aberrant counterparts
14 ability
15 applicants
16 brain
17 cancer
18 cancer stem cell hypothesis
19 cancer stem cells
20 capacity
21 cells
22 centimeters
23 clinical trials
24 complex interactions
25 conventional therapy
26 current therapies
27 description
28 different types
29 differentiated cells
30 differentiated state
31 drugs
32 eradication
33 focus
34 glioblastoma
35 glioblastoma cancer stem cells
36 glioblastoma tumors
37 glioma
38 glioma stem cell differentiation
39 glioma stem cells
40 grade IV gliomas
41 high-grade glioma tumors
42 high-throughput screening
43 human tumors
44 intracranial glioma stem cells model
45 majority
46 malignant form
47 mice
48 modulators
49 molecular alterations
50 most patients
51 new secondary tumor foci
52 non-cancer stem cells
53 normal stem cells
54 nude mice
55 original tumor
56 phenocopy
57 primary CNS tumors
58 proposal
59 reporter system
60 resected area
61 small subpopulation
62 stem cell-like behavior
63 stromal cells
64 trans retinoc acids
65 triple
66 tumor
67 tumor cells
68 tumor recurrence
69 xenotransplantation
70 years
71 schema:name Screening for modulators of glioma stem cells differentiation
72 schema:recipient Nead3b93259894e41bae87c03cfeb6003
73 sg:person.01274336034.51
74 https://www.grid.ac/institutes/grid.32224.35
75 schema:sameAs https://app.dimensions.ai/details/grant/grant.2481830
76 schema:sdDatePublished 2019-03-07T12:14
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher Ne724642a4a924229a995ef408c49f367
79 schema:startDate 2013-01-18T00:00:00Z
80 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=8785102
81 sgo:license sg:explorer/license/
82 sgo:sdDataset grants
83 rdf:type schema:MonetaryGrant
84 N498d26a40d154a86863b02f2f9f7b359 schema:name dimensions_id
85 schema:value 2481830
86 rdf:type schema:PropertyValue
87 Na2252f334af94b0db2c3418d3e087682 schema:name nih_id
88 schema:value R01CA166077
89 rdf:type schema:PropertyValue
90 Ne054f778eb1a4571a4b2f19d3ee8d65b schema:currency USD
91 schema:value 1044772
92 rdf:type schema:MonetaryAmount
93 Ne724642a4a924229a995ef408c49f367 schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 Nead3b93259894e41bae87c03cfeb6003 schema:member sg:person.01274336034.51
96 schema:roleName PI
97 rdf:type schema:Role
98 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
99 rdf:type schema:DefinedTerm
100 sg:person.01274336034.51 schema:affiliation https://www.grid.ac/institutes/grid.32224.35
101 schema:familyName TANNOUS
102 schema:givenName BAKHOS A.
103 rdf:type schema:Person
104 https://www.grid.ac/institutes/grid.32224.35 schema:name MASSACHUSETTS GENERAL HOSPITAL
105 rdf:type schema:Organization
106 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...